POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated...December 28, 2019, Shanghai, China, Elpiscience Biopharma announces the completion of Series B...- FasTCAR-19 (GC007F) shows a high response rate, with 34 of 35 evaluable r/r B-ALL patients...Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the...2019年10月31日PHILADELPHIA, October 31, 2019 -- Tmunity Therapeutics, Inc. in pursuit of its vision to save and...FOSTER CITY, Calif. & SHANGHAI--(BUSINESS WIRE)-- Terns Pharmaceuticals, Inc., a global...BEIJING and SHANGHAI , Oct. 25, 2019 /PRNewswire/ -- Recently, Fountain Medical Development...SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- dMed Biopharmaceutical Co., Ltd. recently announced...More Posts
Company
Shanghai
Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png